KR20050010081A - 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도 - Google Patents

피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도 Download PDF

Info

Publication number
KR20050010081A
KR20050010081A KR10-2005-7000518A KR20057000518A KR20050010081A KR 20050010081 A KR20050010081 A KR 20050010081A KR 20057000518 A KR20057000518 A KR 20057000518A KR 20050010081 A KR20050010081 A KR 20050010081A
Authority
KR
South Korea
Prior art keywords
antibody
antibody fragment
isolated antibody
isolated
cgs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2005-7000518A
Other languages
English (en)
Korean (ko)
Inventor
네리다리오
카르네몰라바르바라
시리아날리지
발차엔리카
카스텔라니파트리치아
피니알레산드로
자르디루치아노
윈터그레그
네리지오반니
보르시라우라
Original Assignee
필로젠 에스.알.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필로젠 에스.알.엘. filed Critical 필로젠 에스.알.엘.
Priority to KR1020067006008A priority Critical patent/KR100741452B1/ko
Publication of KR20050010081A publication Critical patent/KR20050010081A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR10-2005-7000518A 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도 Ceased KR20050010081A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020067006008A KR100741452B1 (ko) 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9610967A GB9610967D0 (en) 1996-05-24 1996-05-24 Specific binding members,materials and methods
GB9610967.3 1996-05-24
PCT/GB1997/001412 WO1997045544A1 (en) 1996-05-24 1997-05-23 Antibodies to the ed-b domain of fibronectin, their construction and uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-1998-0709523A Division KR100494530B1 (ko) 1996-05-24 1997-05-23 피브로넥틴ed-b도메인에대한항체,그제조방법및용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067006008A Division KR100741452B1 (ko) 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도

Publications (1)

Publication Number Publication Date
KR20050010081A true KR20050010081A (ko) 2005-01-26

Family

ID=10794298

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067006008A Expired - Lifetime KR100741452B1 (ko) 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도
KR10-2005-7000518A Ceased KR20050010081A (ko) 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020067006008A Expired - Lifetime KR100741452B1 (ko) 1996-05-24 1997-05-23 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도

Country Status (28)

Country Link
US (3) US7273924B1 (enExample)
EP (1) EP0906426B1 (enExample)
JP (2) JP4750912B2 (enExample)
KR (2) KR100741452B1 (enExample)
CN (1) CN100447159C (enExample)
AT (1) ATE361364T1 (enExample)
AU (1) AU729081B2 (enExample)
BG (1) BG65138B1 (enExample)
BR (1) BR9709350B1 (enExample)
CA (1) CA2256308C (enExample)
CZ (1) CZ295531B6 (enExample)
DE (1) DE69737683T2 (enExample)
DK (1) DK0906426T3 (enExample)
EA (1) EA004329B1 (enExample)
ES (1) ES2286831T3 (enExample)
GB (1) GB9610967D0 (enExample)
HU (1) HUP0200546A2 (enExample)
IL (2) IL127216A0 (enExample)
IS (1) IS2508B (enExample)
NO (1) NO324904B1 (enExample)
NZ (1) NZ333083A (enExample)
PL (1) PL188557B1 (enExample)
PT (1) PT906426E (enExample)
SI (1) SI0906426T1 (enExample)
SK (1) SK285916B6 (enExample)
TR (1) TR199802416T2 (enExample)
UA (1) UA74129C2 (enExample)
WO (1) WO1997045544A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DK1719528T3 (da) * 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
CA2421783A1 (en) * 2000-09-07 2002-03-14 Schering Aktiengesellschaft Receptor in the edb fibronectin domain
IT1317108B1 (it) * 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
EP2239274A1 (en) 2002-01-03 2010-10-13 Bayer Schering Pharma AG New methods for diagnosis and treatment of tumours
PL374386A1 (en) * 2002-03-11 2005-10-17 Philogen S.P.A. Selective targeting of tumor vasculature using antibody molecules
PT2269656E (pt) 2002-07-15 2014-12-02 Univ Texas Anticorpos selecionados e peptídeos de duramicina que se ligam a fosfolipídios aniônicos e aminofosfolipídios e seus usos no tratamento de infecções virais e câncer
BRPI0408315A (pt) 2003-03-14 2006-03-07 Wyeth Corp anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
CA2575675A1 (en) 2004-07-30 2006-03-09 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1803814A1 (en) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
IT1392027B1 (it) * 2008-12-12 2012-02-09 Castellani Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
KR101436222B1 (ko) 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
US9492572B2 (en) 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
US20150183846A1 (en) 2012-06-13 2015-07-02 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
CN104395342B (zh) * 2013-06-06 2017-07-04 合肥立方制药股份有限公司 人源抗纤连蛋白ed‑b结构域的抗体及其用途
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
CN107922483B (zh) 2015-07-16 2021-07-30 纳维格蛋白质有限公司 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
CN108291915B (zh) * 2015-11-16 2021-01-05 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
AU2017311541B2 (en) 2016-08-11 2020-08-13 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
IL310865A (en) 2016-10-17 2024-04-01 Pfizer Antibodies against EDB and antibody-drug conjugates
EP3634999A1 (en) 2017-06-07 2020-04-15 Philogen S.p.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2019062877A1 (zh) * 2017-09-30 2019-04-04 合肥立方制药股份有限公司 结合至纤维连接蛋白b结构域的蛋白
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
CA3148121A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
KR20220130687A (ko) 2019-12-11 2022-09-27 시락 게엠베하 인터내셔날 Ltbr 및 edb 결합 도메인을 포함하는 다중특이성 결합 분자 및 이의 용도
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
JP7690131B2 (ja) 2022-01-04 2025-06-09 フィロジェン ソチエタ ペル アツィオーニ Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
WO2024028258A1 (en) 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
CN119816493A (zh) 2022-09-06 2025-04-11 菲罗化学股份公司 用于靶向递送应用的多价成纤维细胞激活蛋白配体
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3650625T2 (de) 1985-01-28 1997-10-02 Xoma Corp AraB-Promoter und Verfahren zur Herstellung von Polypeptiden einschliesslich Cecropinen mittels mikrobiologischer Verfahren
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4894326A (en) 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
JPH02598A (ja) * 1987-10-09 1990-01-05 De La Rue Co Plc:The 集積回路カード
EP0396612B1 (en) 1988-01-11 1996-07-24 Xoma Corporation Novel plasmid vector with pectate lyase signal sequence
IT1217724B (it) * 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5177015A (en) 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH0276598A (ja) * 1988-09-14 1990-03-15 Fujita Gakuen 抗ｅｄ−ｂ抗体
JPH04169195A (ja) * 1990-10-31 1992-06-17 Fujita Gakuen 抗ｅｄ―ｂモノクローナル抗体
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
WO1994007598A1 (fr) 1992-09-25 1994-04-14 Otsuka Pharmaceutical Factory, Inc. Adsorbant pour fibronectine cellulaire, separation et purification de fibronectine et purification du sang
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6015897A (en) 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ITFI940095A1 (it) 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
WO1996023816A1 (en) 1995-02-01 1996-08-08 British Technology Group Limited Radiolabelled proteins
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6394952B1 (en) 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
EP2239274A1 (en) 2002-01-03 2010-10-13 Bayer Schering Pharma AG New methods for diagnosis and treatment of tumours
JP4169195B2 (ja) * 2003-06-24 2008-10-22 株式会社河合楽器製作所 電子楽音発生装置の記録制御装置

Also Published As

Publication number Publication date
DE69737683T2 (de) 2008-01-10
DK0906426T3 (da) 2007-09-10
BR9709350B1 (pt) 2010-12-14
IL127216A0 (en) 1999-09-22
EA004329B1 (ru) 2004-04-29
BG65138B1 (bg) 2007-03-30
GB9610967D0 (en) 1996-07-31
CA2256308C (en) 2012-03-13
AU729081B2 (en) 2001-01-25
NO985459L (no) 1999-01-22
PT906426E (pt) 2007-07-23
US8703143B2 (en) 2014-04-22
CN100447159C (zh) 2008-12-31
SK285916B6 (sk) 2007-11-02
HUP0200546A2 (en) 2002-07-29
WO1997045544A1 (en) 1997-12-04
CN1219968A (zh) 1999-06-16
KR20060035812A (ko) 2006-04-26
SI0906426T1 (sl) 2007-10-31
IL127216A (en) 2008-11-26
US20140134182A1 (en) 2014-05-15
US7273924B1 (en) 2007-09-25
JP4750912B2 (ja) 2011-08-17
EP0906426A1 (en) 1999-04-07
ES2286831T3 (es) 2007-12-01
CA2256308A1 (en) 1997-12-04
JP2000511416A (ja) 2000-09-05
US9096670B2 (en) 2015-08-04
JP2009050261A (ja) 2009-03-12
EA199801043A1 (ru) 1999-04-29
UA74129C2 (uk) 2005-11-15
NO985459D0 (no) 1998-11-23
NO324904B1 (no) 2007-12-27
BR9709350A (pt) 2000-01-04
IS4883A (is) 1998-10-29
PL330075A1 (en) 1999-04-26
CZ381598A3 (cs) 1999-03-17
ATE361364T1 (de) 2007-05-15
KR100741452B1 (ko) 2007-07-20
TR199802416T2 (xx) 1999-02-22
DE69737683D1 (de) 2007-06-14
PL188557B1 (pl) 2005-02-28
US20080274099A1 (en) 2008-11-06
SK161298A3 (en) 1999-07-12
HK1020990A1 (zh) 2000-05-26
NZ333083A (en) 2000-05-26
BG102950A (en) 1999-08-31
EP0906426B1 (en) 2007-05-02
AU2910197A (en) 1998-01-05
IS2508B (is) 2009-04-15
CZ295531B6 (cs) 2005-08-17

Similar Documents

Publication Publication Date Title
KR100741452B1 (ko) 피브로넥틴 ｅｄ-ｂ 도메인에 대한 항체, 그 제조방법 및용도
Neri et al. Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
AU759207B2 (en) Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
JP4773540B2 (ja) ヒト癌胎児性抗原に対する特異的結合メンバー；材料および方法
IL139452A (en) An isolated antibody related to the fibronectin epitope, a coupling that includes it, and its use in the preparation of a drug for the treatment of angiogenesis-related diseases
KR100494530B1 (ko) 피브로넥틴ed-b도메인에대한항체,그제조방법및용도
HK1020990B (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
MXPA98009732A (en) Antibodies for the fibronectin ed-b domain, its construction and u

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20050111

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050228

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050418

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20051126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050418

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20050228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20060227

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20051126

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20070503

Appeal identifier: 2006101001785

Request date: 20060227

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20060328

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20060328

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20060227

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050617

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060428

Patent event code: PE09021S01D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20070503

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2006101001785

Request date: 20060227

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20070503